| Literature DB >> 25748668 |
Kate Buchacz1, Miao-Jung Chen2, Maree Kay Parisi2, Maya Yoshida-Cervantes2, Erin Antunez2, Viva Delgado2, Nicholas J Moss3, Susan Scheer2.
Abstract
BACKGROUND: Persons with unsuppressed HIV viral load (VL) who disengage from care may experience poor clinical outcomes and potentially transmit HIV. We assessed the feasibility and yield of using the San Francisco Department of Public Health (SFDPH) enhanced HIV surveillance system (eHARS) to identify and re-engage such persons in care.Entities:
Mesh:
Year: 2015 PMID: 25748668 PMCID: PMC4352048 DOI: 10.1371/journal.pone.0118923
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Re-engaging Surveillance-Identified Viremic Persons (RSVP) Project in San Francisco, 2012–2013: Design and Timeline.
Characteristics* of the eligible population and investigated cases, the RSVP project, San Francisco, 2012–2013.
| RSVP Project Eligible (N = 434) | Investigated (N = 282) | Investigated, Interviewed (N = 75) | Investigated, Not Interviewed | p-value | |
|---|---|---|---|---|---|
| Age, median years (IQR) | 45 (37–51) | 44 (36–50) | 45 (37–50) | 44 (35–51) | 0.58 |
| Sex, n (%) | |||||
| Male | 392 (90) | 250 (89) | 65 (87) | 185 (89) | 0.53 |
| Female | 42 (10) | 32 (11) | 10 (13) | 22 (11) | |
| HIV infection risk, n (%) | |||||
| Man who has sex with men | 366 (84) | 228 (81) | 64 (85) | 164 (79) | 0.74 |
| Heterosexual | 27 (6) | 27 (10) | 5 (7) | 22 (11) | |
| Injection drug user | 27 (6) | 16 (6) | 4 (5) | 12 (6) | |
| Other or unknown | 14 (3) | 11 (4) | 2 (3) | 9 (4) | |
| Race/ethnicity, n (%) | |||||
| Non-Hispanic white | 229 (53) | 129 (46) | 32 (43) | 97 (47) | 0.39 |
| Non-Hispanic black | 86 (20) | 65 (23) | 20 (27) | 45 (22) | |
| Non-Hispanic Asian/Pacific Islander | 22 (5) | 20 (7) | 2 (3) | 18 (9) | |
| Hispanic | 82 (19) | 63 (22) | 20 (27) | 43 (21) | |
| Other | 13 (3) | 4 (1) | 1 (1) | 3 (1) | |
| Unknown | 2 (0) | 1 (0) | 0 (0) | 1 (0) | |
| Year of HIV diagnosis, n (%) | |||||
| ≤ 1994 | 85 (20) | 42 (15) | 14 (19) | 28 (14) | 0.53 |
| 1995–2000 | 89 (21) | 47 (17) | 11 (15) | 36 (17) | |
| ≥ 2001 | 260 (60) | 193 (68) | 50 (67) | 143 (69) | |
| County of residence, n (%) | |||||
| San Francisco (SF) | 260 (60) | 211 (75) | 59 (79) | 152 (73) | 0.11 |
| Greater Bay Area other than SF | 71 (16) | 62 (22) | 15 (20) | 47 (23) | |
| Other California county | 61 (14) | 1 (0) | 1 (1) | 0 (0) | |
| Other State | 33 (8) | 0 (0) | 0 (0) | 0 (0) | |
| Missing | 9 (2) | 8 (3) | 0 (0) | 8 (4) | |
| Qualifying | |||||
| > 200–999 copies/mL | 70 (16) | 34 (12) | 11 (15) | 23 (11) | 0.20 |
| 1,000–9,999 copies/mL | 129 (30) | 93 (33) | 27 (36) | 66 (32) | |
| 10,000–100,000 copies/mL | 164 (38) | 112 (40) | 31 (41) | 81 (39) | |
| > 100,000 copies/mL | 71 (16) | 43 (15) | 6 (8) | 37 (18) | |
| CD4 count | |||||
| < 200 cells/mm3 | 112 (26) | 70 (25) | 13 (17) | 57 (28) | 0.09 |
| 200–349 cells/mm3 | 77 (18) | 51 (18) | 21 (28) | 30 (14) | |
| 350–499 cells/mm3 | 68 (16) | 44 (16) | 11 (15) | 33 (16) | |
| 500+ cells/mm3 | 138 (32) | 97 (34) | 26 (35) | 71 (34) | |
| Missing | 39 (9) | 20 (7) | 4 (5) | 16 (8) | |
| Any ARV use, n (%) | |||||
| Yes | 246 (57) | 145 (51) | 39 (52) | 106 (51) | 1.00 |
| No | 188 (43) | 137 (49) | 36 (48) | 101 (49) |
* Based on eHARS data as of index date, 04/20/2012, unless otherwise specified.
† The 207 persons who were investigated but ultimately not interviewed included 59 (29%) who were found to be either ineligible during investigation (non-English speakers), deceased, or residing outside of the Greater Bay Area.
‡ p-values comparing the 75 persons interviewed and 207 not interviewed were calculated usingWilcoxon-Mann-Whitney test or Fisher’s exact test.
§ Qualifying HIV viral load: last measurement from January 20, 2011 to July 20, 2011 time period.
ǁ Closest CD4 cell count result obtained between six months prior and three months after the qualifying viral load collection date.
Abbreviations: ARV; antiviral; IQR; interquartile range.
Fig 2RSVP Project Implementation Flowchart.
Fig 3Disposition for 282 Investigated Cases, the RSVP Project, San Francisco, 2012–2013 (n = 282).
Match-back to eHARS data available 12 months after index date to confirm persons’ original eligibility and to assess re-engagement in care based on new HIV laboratory data, the RSVP Project, San Francisco, 2012–2013.
| RSVP Project-eligible | Investigated | Interviewed | |
|---|---|---|---|
|
| N = 434 | N = 282 | N = 75 |
|
| |||
| Not eligible | 110 (25%) | 61 (22%) | 25 (33%) |
|
| N = 324 | N = 221 | N = 50 |
|
| |||
|
| |||
| ≥ 1 VL or CD4 cell count | 249 (57%) | 181 (64%) | 62 (83%) |
| ≥ 2 labs (VL or CD4 cell count) ≥ 90 days apart | 104 (24%) | 80 (28%) | 35 (47%) |
|
| |||
| ≥ 1 VL or CD4 cell count | 171 (53%) | 134 (61%) | 41 (82%) |
| ≥ 2 labs (VL or CD4 cell count) ≥ 90 days apart | 73 (23%) | 60 (27%) | 24 (48%) |
NOTE: VL, viral load; index date was April 20, 2012.
* Subset of persons originally thought to be eligible for the RSVP project who, in retrospect, were not eligible based on additional laboratory results performed before index date but only reported to eHARS during the 12 months after the index date.